Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: SELL (auto-tracking)
3.69% $16.84
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 512.65 mill |
EPS: | -1.960 |
P/E: | -8.59 |
Earnings Date: | Mar 04, 2024 |
SharesOutstanding: | 89.83 mill |
Avg Daily Volume: | 1.305 mill |
RATING 2024-03-27 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -8.59 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.18x |
Company: PE -8.59 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.122 (-100.73%) $-16.96 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 15.84 - 17.84 ( +/- 5.92%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-20 | Kim Richard J | Buy | 147 000 | Stock Option (Right to Buy) |
2024-02-20 | Mchugh Thomas S | Buy | 157 500 | Stock Option (Right to Buy) |
2024-02-20 | Divis Gregory J | Buy | 600 000 | Stock Option (Right to Buy) |
2024-01-16 | Mchugh Thomas S | Buy | 2 000 | ADSs |
2023-12-28 | Mccamish Mark Anthony | Sell | 75 000 | ADSs |
INSIDER POWER |
---|
81.02 |
Last 94 transactions |
Buy: 6 417 800 | Sell: 317 647 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $16.84 (3.69% ) |
Volume | 0.356 mill |
Avg. Vol. | 1.305 mill |
% of Avg. Vol | 27.24 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $14.80 | N/A | Active |
---|
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.